Published Date:2023-07-14 Original Link:https://www.onenessbio.com/en/news_detail234_2.htm No 2 Date of announcement 2023/07/14 Time of announcement 20:18:26 Subject Fespixon cream has been approved to be reimbursed by the National Health Insurance To which item it meets paragraph 53 Date of events 2023/07/14 Statement Date of occurrence of the event:2023/07/14 Company name:ONENESS BIOTECH CO., LTD. Relationship to the Company...Read More

Published Date:2023-07-14 Original Link:https://www.onenessbio.com/en/news_detail233_2.htm No 1 Date of announcement 2023/07/14 Time of announcement 20:16:59 Subject FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved by Malaysia NPRA To which item it meets paragraph 10 Date of events 2023/07/14 Statement Product:FESPIXON, a new drug for the treatment of diabetic foot ulcers Mass...Read More

Published Date:2023-07-09 Original Link:https://www.onenessbio.com/en/news_detail232_2.htm No 1 Date of announcement 2023/07/09 Time of announcement 22:53:48 Subject Clarification on the media report with regards to the registration approval on Fespixon by Malaysia MOH To which item it meets paragraph 53 Date of events 2023/07/08 Statement Date of occurrence of the event:2023/07/08 Company name: Oneness Biotech Co., Ltd....Read More

Published Date:2023-06-29 Original Link:https://www.onenessbio.com/en/news_detail231_3.htm No 2 Date of announcement 2023/06/29 Time of announcement 22:34:37 Subject Oneness was notified today that Bonvadis, the wound care topical cream has submitted medical device registration to South African Health Products Regulatory Authority. To which item it meets paragraph 10 Date of events 2023/06/29 Statement Product:Bonvadis topical cream for wound...Read More

Published Date:2023-06-28 Original Link:https://www.onenessbio.com/en/news_detail230_3.htm No 2 Date of announcement 2023/06/29 Time of announcement  00:14:40 Subject SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by TFDA to proceed with a Ph2 study To which item it meets paragraph 10 Date of events 2023/06/28 Statement Product:SNS812, a broad-spectrum siRNA...Read More

Published Date:2023-06-28 Original Link:https://www.onenessbio.com/en/news_detail229_3.htm No 1 Date of announcement 2023/06/28 Time of announcement 18:48:09 Subject Oneness Biotech Co., Ltd. receives a Vietnamese patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2023/06/28 Statement Date of occurrence of the event:2023/06/28 Company...Read More

Published Date:2023-06-21 Original Link:https://www.onenessbio.com/en/news_detail228_3.htm No 2 Date of announcement 2023/06/21 Time of announcement 17:31:30 Subject Oneness announces the information about the investor’s conference of 2023 Q2. To which item it meets paragraph 12 Date of events 2023/06/30 Statement Date of institutional investor conference:2023/06/30 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference:Online Investor...Read More

Published Date:2023-06-21 Original Link:https://www.onenessbio.com/en/news_detail227_3.htm No 1 Date of announcement 2023/06/21 Time of announcement 16:55:57 Subject The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at 2023 ADA’s 83rd Scientific Sessions. To which item it meets paragraph 12 Date of events 2023/06/24...Read More

Published Date:2023-06-09 Original Link:https://www.onenessbio.com/en/news_detail226_3.htm No 1 Date of announcement 2023/06/09 Time of announcement 17:31:30 Subject Oneness submitted an IND to TFDA for a phase II clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai) To which item it meets paragraph 10 Date of events 2023/06/09 Statement Product:SNS812, a broad-spectrum siRNA against SARS-CoV-2...Read More

Published Date:2023-06-06 Original Link:https://www.onenessbio.com/en/news_detail224_3.htm No 1 Date of announcement 2023/06/06 Time of announcement 18:12:22 Subject The National Agency of Drug and Food Control(Badan Pengawas Obat dan Makanan; BPOM) has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon To which item it meets paragraph 10 Date of events 2023/06/06 Statement Product:ON101, diabetic...Read More